Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 29, 2014

View Archived Issues

Korean group prepares new monoclonal antibodies

Cedars-Sinai begins phase I trial of brain cancer vaccine

Venaxis completes enrollment in pivotal U.S. trial of APPY1 Test for appendicitis

GERD linked to FOXF1 and MHC locus gene polymorphisms

Researchers at Esteve design novel sigma1 receptor ligands

Tekmira commences phase I trial of TKM-100802

New casein kinase 2 inhibitors disclosed by Bristol-Myers Squibb

Genentech and Roche disclose new ROR-gamma modulators

PARSiFAL trial to investigate BAY-1067197 in heart failure

Mallinckrodt begins patient recruitment in phase I trial of MP-3549.1 in advanced solid tumors

Patient recruitment begins in phase I trial of Ribological's personalized anticancer vaccine

Transgene prepares novel tuberculosis vaccines

DioGenix discloses new data supporting efficacy of multiple sclerosis assay

Maruho to take over marketing rights for Protopic ointment in Japan

Data presented from AIMSPRO study in diffuse systemic sclerosis

OncoCyte commences clinical development of bladder cancer diagnostics in U.S. and China

Alcobra reports promising results from new study of MG-01CI in animal model of fragile X syndrome

Phase I study of A*STAR and Cytos' H1N1 influenza vaccine meets primary immunogenicity endpoint

FDA committee recommends approval of Ragwitek BLA

Amgen's LAPLACE-2 phase III trial of evolocumab in combination with statins meets primary endpoints

Oncolys BioPharma commences phase I/II trial of Telomelysin in Korea and Taiwan

Sosei offers development update on glycopyrronium bromide programs

VCN Biosciences to advance VCN-01 oncolytic adenovirus to clinic

PARP-1 inhibitors developed at Lupin

Astellas reports melatonin agonists for urinary incontinence

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...